Disease · EFO_0010682

liver transplant

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. liver transplant. Diseases, record EFO_0010682. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0010682

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: liver transplant; Open Targets
Open Targets ID: EFO_0010682; Open Targets
Other names: liver transplantation, transplant of liver, transplantation of liver; Open Targets
MeSH: D016031; MeSH
NCI Thesaurus: C15271; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 22 drugs, from EMA Human Drugs; Open Targets

Drugs22

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TACROLIMUS	CHEMBL3989887	Small molecule	Approval	EMA Human Drugs	26	25	25	Drugs and targets
HEPATITIS B IMMUNE GLOBULIN	CHEMBL2108512		Approval	EMA Human Drugs	1	0	0	Drugs and targets
EVEROLIMUS	CHEMBL1908360	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
MYCOPHENOLATE MOFETIL	CHEMBL1456	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
MYCOPHENOLIC ACID	CHEMBL866	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
BASILIXIMAB	CHEMBL1201439	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	CHEMBL2108981		Phase 3	ClinicalTrials.gov	2	2	0	Drugs and targets
CYCLOSPORINE	CHEMBL160	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
FIBRINOGEN, HUMAN	CHEMBL2109072		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 22

See all 22 drugs

Targets41

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	3	FK506-binding protein 1A inhibitor	Approval	https://conductscience.org/library/genes/2280	Drugs and targets
IMPDH1	Inosine-5'-monophosphate dehydrogenase (IMPDH)	3	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 3	https://conductscience.org/library/genes/3614	Drugs and targets
IMPDH2	Inosine-5'-monophosphate dehydrogenase (IMPDH)	3	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 3	https://conductscience.org/library/genes/3615	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2559	Drugs and targets

1 to 10 of 41

See all 41 targets

Trials44

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00622869	Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients	Phase 3	719	2013-05-20	Liver Transplantation	EVEROLIMUS, TACROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00086346	Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients	Phase 3	607	2009-09-07	Liver Transplantation	CYCLOSPORINE, SIROLIMUS, TACROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01625377	A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients	Phase 3	188	2016-04-27	Liver Transplantation	EVEROLIMUS, MYCOPHENOLIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02115113	REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy	Phase 3	78	2019-02-28	Liver Transplantation	EVEROLIMUS, TACROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00149890	Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids	Phase 3	77	2011-09-22	Liver Transplantation, Infection	BASILIXIMAB, CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT00336817	A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients	Not applicable	30	2017-03-09	Immunosuppression	MYCOPHENOLATE MOFETIL, MYCOPHENOLATE SODIUM	Its record names the disease	ClinicalTrials.gov
NCT00282256	A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients	Phase 2	19	2013-10-17	Liver Transplantation	TACROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01230502	Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation	Not applicable	11	2014-05-07	Liver Transplant	MYCOPHENOLIC ACID	Its record names the disease	ClinicalTrials.gov
NCT07157631	Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial	Not applicable	1,546		Liver Transplantation, Tranexamic Acid, End-stage Liver Disease (ESLD)	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01011205	Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation	Phase 3	893		Liver Transplantation	BASILIXIMAB, MYCOPHENOLATE MOFETIL, TACROLIMUS	Its record names the disease	ClinicalTrials.gov

1 to 10 of 44

See all 44 trials

Comparisons in its trials11

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Tacrolimus vs Everolimus (RAD001): serious adverse events	28 of 94	42 of 90	184	NCT01625377	Trial comparisons
With Intraoperative Steroids vs Without Intraoperative Steroids: Number of Participants With Biopsy Proven Acute Rejection (BPAR) Episodes Within the First Three Months	20 of 39	26 of 38	77	NCT00149890	Trial comparisons
With Intraoperative Steroids vs Without Intraoperative Steroids: serious adverse events	18 of 39	23 of 38	77	NCT00149890	Trial comparisons
Myfortic Group vs CellCept Group: serious adverse events	0 of 15	0 of 15	30	NCT00336817	Trial comparisons
Myfortic Group vs CellCept Group: Drug Discontinuation Due to Side Effects	1 of 14	2 of 15	29	NCT00336817	Trial comparisons
Myfortic Group vs CellCept Group: Number of Participants With Bone Marrow Suppression	0 of 14	0 of 15	29	NCT00336817	Trial comparisons
Myfortic Group vs CellCept Group: Number of Participants With Neurotoxicity	0 of 14	0 of 15	29	NCT00336817	Trial comparisons
Myfortic Group vs CellCept Group: Incidence of Biopsy-proven Acute Cellular Rejection During the Study Period	2 of 14	1 of 15	29	NCT00336817	Trial comparisons
Myfortic Group vs CellCept Group: Incidence of Cytomegalovirus Infection or Disease During the Study Period	0 of 14	0 of 15	29	NCT00336817	Trial comparisons
Myfortic Group vs CellCept Group: Incidence of Graft Loss or Death During the Study Period	0 of 14	0 of 15	29	NCT00336817	Trial comparisons

1 to 10 of 11

See all 11 comparisons in its trials

Papers from its trials16

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39152310	DERIVED	1	PubMed
37919695	DERIVED	1	PubMed
37170284	DERIVED	1	PubMed
32991411	DERIVED	1	PubMed
32911703	DERIVED	1	PubMed
31003735	DERIVED	1	PubMed
29135993	DERIVED	1	PubMed
28990201	DERIVED	1	PubMed
28817434	DERIVED	1	PubMed
28295581	DERIVED	1	PubMed

1 to 10 of 16

See all 16 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0010682

GET https://conductscience.org/api/diseases/v1/EFO_0010682/drugs?page=2

API reference For AI assistants